Replimune (REPL) News and press releases

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023

5 Jan 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

EF Hutton Initiates Coverage On Replimune Group with Buy Rating, Announces Price Target of $60

5 Jan 23

News, Price Target, Initiation, Analyst Ratings

EF Hutton analyst Tony Butler initiates coverage on Replimune Group (NASDAQ:REPL) with a Buy rating and announces Price Target of $60.

Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform

12 Dec 22

Analyst Color, Biotech, News, Health Care, Price Target, Reiteration, Small Cap, Analyst Ratings, Movers, Trading Ideas, General

Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.

PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday

12 Dec 22

News, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas

BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $70

12 Dec 22

News, Price Target, Analyst Ratings

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $40 to $70.

Reported Late Thursday, Replimune Announces Pricing Of $225M Public Offering Of 5,374,486 Shares Of Common Stock At A Price Of $23.50/Share

9 Dec 22

News, Offerings

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering

Analyst Ratings for Replimune Group

7 Dec 22

Analyst Ratings

SVB Leerink Maintains Outperform on Replimune Group, Raises Price Target to $34

7 Dec 22

News, Price Target, Analyst Ratings

SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and raises the price target from $30 to $34.

Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session

7 Dec 22

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC met the primary endpoint.

12 Health Care Stocks Moving In Wednesday's Intraday Session

7 Dec 22

Movers

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients

7 Dec 22

Biotech, Large Cap, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

7 Dec 22

Movers

Replimune Enters Clinical Collaboration Agreement With Roche For Development Of RP3 In Colorectal Cancer And Hepatocellular Carcinoma

7 Dec 22

Biotech, General

P3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 Jan 23

Markets, Press Releases

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies

Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

4 Jan 23

News, Management, Press Releases

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies

Replimune Announces Pricing of Public Offering

8 Dec 22

Markets, Press Releases

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today

Replimune Announces Proposed Public Offering

7 Dec 22

Markets, Press Releases

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

7 Dec 22

News, Press Releases

RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%, with clinically

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

7 Dec 22

Health Care, Press Releases

RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma (HCC) Includes cost

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

23 Nov 22

News, Press Releases

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies,